High-dose chemotherapy and total-body irradiation, which are performed as the conditioning regimen for hematopoietic cell transplantation (HCT), are associated with xerostomia. Oralbalance® has been reported to alleviate the symptoms of post-radiotherapy xerostomia in head and neck cancer patients [1, 4] . Therefore, we postulated that this product may be effective in HCT patients. Based on our in vitro results, we concluded that Oralbalance® does not facilitate increases in microorganisms in the HCT period. Oral care with Oralbalance does not promote infection in patients undergoing HCT [2] . From our in vivo results, in neutropenic patients undergoing HCT, Oralbalance® did not increase the total counts of oral mucosal bacteria beyond the range found in healthy controls. Oral care using Oralbalance® may alleviate the symptoms induced by hyposalivation without promoting infection [3] . These antibacterial results were related to the enzymes present in the formulation. In our previous in vitro study, we demonstrated that the antibacterial effects of Oralbalance® were mainly due to antimicrobial enzymes of salivary origin, i.e., lactoperoxidase, lysozyme, and lactoferrin. However, these antibacterial enzymes have been removed with the recent formula change, and the product is now composed of glycerin, water, sorbitol, xylitol, carbomer, hydroxyethyl cellulose, sodium hydroxide, and propylparaben (cited from http://www.biotene.com/products/gel, accessed on 13 June 2014) with no enzymes. Therefore, we cannot guarantee our results with the new formula, despite its use of the same name. Further studies on the product with the new formula are required.
